retatrutide eli lilly phase 2 results Lilly's triple agonist, retatrutide, successful in two additional 3 obesity trials, delivering significant improvements in weight and A1C Lilly's triple agonist delivers up

Clinical trials show that discontinuing GLP-1 therapy leads to weight regain in approximately 70% of patients within one year, underscoring why these medications function best as long-term treatment rather than temporary interventions

What about Ozempic vs Wegovy vs Mounjaro vs Zepbound

For many people, these medications restore metabolic signaling that hasnt worked properly in years - maybe decades

PlexusDx's Precision Peptide Genetic Test maps 14 metabolic and neurological pathways across 49 peptides to identify your individual predisposition to mood shifts on GLP-1 therapy

In the 48-week phase 2 trial published in the New England Journal of Medicine, retatrutide at the 12mg weekly dose produced an average body weight reduction of 24.2%

Anorectics and Anabolics To understand how to improve weight loss, we need to understand how GLP-1s work